Skip to main content
Erschienen in:

24.06.2022 | Endokrine Tumoren | Leitthema

Systemtherapie des anaplastischen Schilddrüsenkarzinoms

verfasst von: Prof. Dr. Christine Dierks

Erschienen in: Die Onkologie | Ausgabe 8/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Anaplastische Schilddrüsenkarzinome (ATC) sind eine seltene, aber hoch aggressive Subgruppe der Schilddrüsenkarzinome mit einer Überlebenszeit von nur wenigen Monaten trotz multimodaler Therapie. Im frühen Stadium sind die Chirurgie und die Radiochemotherapie entscheidend für das Überleben der Patient*innen. Da jedoch über 90 % der ATC metastasieren, ist anschließend eine effektive Systemtherapie von essentieller Bedeutung.

Ziel

Ziel war die Darstellung aller klassischen und neuen systemischen Therapieoptionen beim ATC sowie der dazu notwendigen zielgerichteten molekularen Diagnostik.

Methoden

Es handelt sich um eine selektive Literaturrecherche sowie Auswertung des eigenen Patientenkollektivs.

Ergebnisse

Der Review fasst alle aktuellen systemischen Therapiekonzepte von klassischen Chemotherapien über molekularpathologische zielgerichtete Therapien mit Kinaseinhibitoren sowie immuntherapeutische Ansätze zusammen.

Schlussfolgerung

Durch diese neuen Therapiekonzepte kann die Prognose der Patient*innen mit ATC entscheidend verbessert werden.
Literatur
2.
Zurück zum Zitat Perri F, Lorenzo GD, Scarpati GD, Buonerba C (2011) Anaplastic thyroid carcinoma: a comprehensive review of current and future therapeutic options. World J Clin Oncol 2:150–157PubMedPubMedCentralCrossRef Perri F, Lorenzo GD, Scarpati GD, Buonerba C (2011) Anaplastic thyroid carcinoma: a comprehensive review of current and future therapeutic options. World J Clin Oncol 2:150–157PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Prasongsook N et al (2017) Survival in response to multimodal therapy in anaplastic thyroid cancer. J Clin Endocrinol Metab 102:4506–4514PubMedCrossRef Prasongsook N et al (2017) Survival in response to multimodal therapy in anaplastic thyroid cancer. J Clin Endocrinol Metab 102:4506–4514PubMedCrossRef
5.
Zurück zum Zitat Smallridge RC, Copland JA (2010) Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol 22:486–497CrossRef Smallridge RC, Copland JA (2010) Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol 22:486–497CrossRef
6.
Zurück zum Zitat Wendler J et al (2016) Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany. Eur J Endocrinol 175:521–529PubMedCrossRef Wendler J et al (2016) Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany. Eur J Endocrinol 175:521–529PubMedCrossRef
7.
Zurück zum Zitat Salehian B, Liem SY, Mojazi Amiri H, Maghami E, Clinical Trials in Management of Anaplastic Thyroid Carcinoma (2019) Progressions and Set Backs: A Systematic Review. Int J Endocrinol Metab 17:e67759PubMedPubMedCentral Salehian B, Liem SY, Mojazi Amiri H, Maghami E, Clinical Trials in Management of Anaplastic Thyroid Carcinoma (2019) Progressions and Set Backs: A Systematic Review. Int J Endocrinol Metab 17:e67759PubMedPubMedCentral
8.
Zurück zum Zitat Dierks C et al (2021) Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid 31:1076–1085PubMedPubMedCentralCrossRef Dierks C et al (2021) Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid 31:1076–1085PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Nikiforova MN et al (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399–5404PubMedCrossRef Nikiforova MN et al (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399–5404PubMedCrossRef
11.
Zurück zum Zitat Takano T, Ito Y, Hirokawa M, Yoshida H, Miyauchi A (2007) BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas. Br J Cancer 96:1549–1553PubMedPubMedCentralCrossRef Takano T, Ito Y, Hirokawa M, Yoshida H, Miyauchi A (2007) BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas. Br J Cancer 96:1549–1553PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Xu B et al (2020) Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases. Thyroid 30:1505–1517PubMedPubMedCentralCrossRef Xu B et al (2020) Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases. Thyroid 30:1505–1517PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Yoo SK et al (2019) Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer. Nat Commun 10:2764PubMedPubMedCentralCrossRef Yoo SK et al (2019) Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer. Nat Commun 10:2764PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Duan H et al (2019) Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing. Histopathology 75:890–899PubMedCrossRef Duan H et al (2019) Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing. Histopathology 75:890–899PubMedCrossRef
15.
Zurück zum Zitat Bonhomme B et al (2017) Molecular pathology of anaplastic thyroid carcinomas: a retrospective study of 144 cases. Thyroid 27:682–692PubMedCrossRef Bonhomme B et al (2017) Molecular pathology of anaplastic thyroid carcinomas: a retrospective study of 144 cases. Thyroid 27:682–692PubMedCrossRef
16.
Zurück zum Zitat Kunstman JW et al (2015) Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. Hum Mol Genet 24:2318–2329PubMedPubMedCentralCrossRef Kunstman JW et al (2015) Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. Hum Mol Genet 24:2318–2329PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, Nikiforov YE (2002) PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 26:1016–1023PubMedCrossRef Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, Nikiforov YE (2002) PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 26:1016–1023PubMedCrossRef
20.
Zurück zum Zitat Ekman ET, Lundell G, Tennvall J, Wallin G (1990) Chemotherapy and multimodality treatment in thyroid carcinoma. Otolaryngol Clin North Am 23:523–527PubMedCrossRef Ekman ET, Lundell G, Tennvall J, Wallin G (1990) Chemotherapy and multimodality treatment in thyroid carcinoma. Otolaryngol Clin North Am 23:523–527PubMedCrossRef
21.
Zurück zum Zitat Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R (1985) A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155–2160PubMedCrossRef Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R (1985) A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155–2160PubMedCrossRef
22.
Zurück zum Zitat Ain KB, Egorin MJ, DeSimone PA (2000) Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 10:587–594PubMedCrossRef Ain KB, Egorin MJ, DeSimone PA (2000) Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 10:587–594PubMedCrossRef
23.
Zurück zum Zitat Sosa JA et al (2014) Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid 24:232–240PubMedCrossRef Sosa JA et al (2014) Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid 24:232–240PubMedCrossRef
24.
Zurück zum Zitat Crispo F, Notarangelo T, Pietrafesa M, Lettini G, Storto G, Sgambato A, Maddalena F, Landriscina M (2019) BRAF inhibitors in thyroid cancer: Clinical impact, mechanisms of resistance and future perspectives. Cancers (Basel) 11(9):1388. https://doi.org/10.3390/cancers11091388CrossRef Crispo F, Notarangelo T, Pietrafesa M, Lettini G, Storto G, Sgambato A, Maddalena F, Landriscina M (2019) BRAF inhibitors in thyroid cancer: Clinical impact, mechanisms of resistance and future perspectives. Cancers (Basel) 11(9):1388. https://​doi.​org/​10.​3390/​cancers11091388CrossRef
25.
Zurück zum Zitat Subbiah V et al (2018) Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol 36:7–13PubMedCrossRef Subbiah V et al (2018) Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol 36:7–13PubMedCrossRef
26.
Zurück zum Zitat Wang JR et al (2019) Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF(V600E)-mutated anaplastic thyroid carcinoma. Thyroid 29:1036–1043PubMedPubMedCentralCrossRef Wang JR et al (2019) Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF(V600E)-mutated anaplastic thyroid carcinoma. Thyroid 29:1036–1043PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Ciampi R et al (2019) Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing. iScience 20:324–336PubMedPubMedCentralCrossRef Ciampi R et al (2019) Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing. iScience 20:324–336PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Liu Z et al (2008) Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3‑kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 93:3106–3116PubMedCrossRef Liu Z et al (2008) Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3‑kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 93:3106–3116PubMedCrossRef
29.
Zurück zum Zitat Landa I et al (2016) Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 126:1052–1066PubMedPubMedCentralCrossRef Landa I et al (2016) Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 126:1052–1066PubMedPubMedCentralCrossRef
30.
31.
Zurück zum Zitat Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA (1997) Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 57:1690–1694PubMed Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA (1997) Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 57:1690–1694PubMed
32.
Zurück zum Zitat Ciampi R, Nikiforov YE (2007) RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 148:936–941PubMedCrossRef Ciampi R, Nikiforov YE (2007) RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 148:936–941PubMedCrossRef
33.
Zurück zum Zitat Ciampi R, Giordano TJ, Wikenheiser-Brokamp K, Koenig RJ, Nikiforov YE (2007) HOOK3-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma. Endocr Relat Cancer 14:445–452PubMedCrossRef Ciampi R, Giordano TJ, Wikenheiser-Brokamp K, Koenig RJ, Nikiforov YE (2007) HOOK3-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma. Endocr Relat Cancer 14:445–452PubMedCrossRef
34.
Zurück zum Zitat Vanden PB et al (2017) Pediatric, adolescent, and young adult thyroid carcinoma harbors frequent and diverse targetable genomic alterations, including Kinase fusions. Oncologist 22:255–263CrossRef Vanden PB et al (2017) Pediatric, adolescent, and young adult thyroid carcinoma harbors frequent and diverse targetable genomic alterations, including Kinase fusions. Oncologist 22:255–263CrossRef
35.
Zurück zum Zitat Su X et al (2016) Radiation exposure, young age, and female gender are associated with high prevalence of RET/PTC1 and RET/PTC3 in papillary thyroid cancer: a meta-analysis. Oncotarget 7:16716–16730PubMedPubMedCentralCrossRef Su X et al (2016) Radiation exposure, young age, and female gender are associated with high prevalence of RET/PTC1 and RET/PTC3 in papillary thyroid cancer: a meta-analysis. Oncotarget 7:16716–16730PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Wirth LJ et al (2020) Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med 383:825–835PubMedCrossRef Wirth LJ et al (2020) Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med 383:825–835PubMedCrossRef
37.
38.
Zurück zum Zitat Amatu A et al (2019) Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. Ann Oncol 30(Suppl 8):viii5–viii15PubMedPubMedCentralCrossRef Amatu A et al (2019) Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. Ann Oncol 30(Suppl 8):viii5–viii15PubMedPubMedCentralCrossRef
39.
40.
41.
Zurück zum Zitat Doebele RC et al (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol 21:271–282PubMedCrossRef Doebele RC et al (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol 21:271–282PubMedCrossRef
42.
43.
Zurück zum Zitat Matsui J et al (2008) E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 122:664–671PubMedCrossRef Matsui J et al (2008) E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 122:664–671PubMedCrossRef
44.
Zurück zum Zitat Okamoto K et al (2013) Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett 340:97–103PubMedCrossRef Okamoto K et al (2013) Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett 340:97–103PubMedCrossRef
45.
Zurück zum Zitat Yamamoto Y et al (2014) Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell 6:18PubMedPubMedCentralCrossRef Yamamoto Y et al (2014) Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell 6:18PubMedPubMedCentralCrossRef
46.
Zurück zum Zitat Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372(7):621–630. https://doi.org/10.1056/NEJMoa1406470CrossRefPubMed Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372(7):621–630. https://​doi.​org/​10.​1056/​NEJMoa1406470CrossRefPubMed
47.
Zurück zum Zitat Kiyota N et al (2015) Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci 106:1714–1721PubMedPubMedCentralCrossRef Kiyota N et al (2015) Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci 106:1714–1721PubMedPubMedCentralCrossRef
48.
Zurück zum Zitat Schlumberger M, Tahara M, Wirth LJ (2015) Lenvatinib in radioiodine-refractory thyroid cancer. N Engl J Med 372:1868PubMedCrossRef Schlumberger M, Tahara M, Wirth LJ (2015) Lenvatinib in radioiodine-refractory thyroid cancer. N Engl J Med 372:1868PubMedCrossRef
49.
50.
Zurück zum Zitat Takahashi S et al (2019) A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Future Oncol 15:717–726PubMedCrossRef Takahashi S et al (2019) A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Future Oncol 15:717–726PubMedCrossRef
52.
Zurück zum Zitat Wirth LJ et al (2021) Open-label, single-arm, multicenter, phase II trial of Lenvatinib for the treatment of patients with anaplastic thyroid cancer. J Clin Oncol 39:2359–2366PubMedPubMedCentralCrossRef Wirth LJ et al (2021) Open-label, single-arm, multicenter, phase II trial of Lenvatinib for the treatment of patients with anaplastic thyroid cancer. J Clin Oncol 39:2359–2366PubMedPubMedCentralCrossRef
53.
Zurück zum Zitat Adam P et al (2021) FGF-receptors and PD-L1 in anaplastic and poorly differentiated thyroid cancer: evaluation of the preclinical rationale. Front Endocrinol 12:712107CrossRef Adam P et al (2021) FGF-receptors and PD-L1 in anaplastic and poorly differentiated thyroid cancer: evaluation of the preclinical rationale. Front Endocrinol 12:712107CrossRef
54.
Zurück zum Zitat Gandhi L et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078–2092PubMedCrossRef Gandhi L et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078–2092PubMedCrossRef
55.
Zurück zum Zitat Garon EB et al (2019) Five-year overall survival for patients with advanced nonsmall-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol 37:2518–2527PubMedPubMedCentralCrossRef Garon EB et al (2019) Five-year overall survival for patients with advanced nonsmall-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol 37:2518–2527PubMedPubMedCentralCrossRef
56.
Zurück zum Zitat Villaruz LC et al (2019) Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small-cell lung cancer in clinical practice. Histopathology 74:269–275PubMedCrossRef Villaruz LC et al (2019) Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small-cell lung cancer in clinical practice. Histopathology 74:269–275PubMedCrossRef
57.
59.
Zurück zum Zitat Gunda V et al (2019) Anti-PD-1/PD-L1 therapy augments lenvatinib’s efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer. Int J Cancer 144:2266–2278PubMedCrossRef Gunda V et al (2019) Anti-PD-1/PD-L1 therapy augments lenvatinib’s efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer. Int J Cancer 144:2266–2278PubMedCrossRef
60.
Zurück zum Zitat Makker V et al (2019) Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 20:711–718PubMedCrossRef Makker V et al (2019) Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 20:711–718PubMedCrossRef
61.
Zurück zum Zitat Taylor MH et al (2021) The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors. Future Oncol 17:637–648PubMedCrossRef Taylor MH et al (2021) The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors. Future Oncol 17:637–648PubMedCrossRef
62.
Zurück zum Zitat Finn RS et al (2020) Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol 38:2960–2970PubMedPubMedCentralCrossRef Finn RS et al (2020) Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol 38:2960–2970PubMedPubMedCentralCrossRef
Metadaten
Titel
Systemtherapie des anaplastischen Schilddrüsenkarzinoms
verfasst von
Prof. Dr. Christine Dierks
Publikationsdatum
24.06.2022
Verlag
Springer Medizin
Erschienen in
Die Onkologie / Ausgabe 8/2022
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-022-01198-5

Weitere Artikel der Ausgabe 8/2022

Die Onkologie 8/2022 Zur Ausgabe

Passend zum Thema

ANZEIGE

AGO-Leitlinie 2024: Update zu CDK4 & 6 Inhibitoren

Die Kommission Mamma der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) hat am 02. März 2024 ihre aktualisierten Empfehlungen präsentiert.[1,2] Welchen Stellenwert CDK4 & 6 Inhibitoren in der Therapie des Hormonrezeptor-positiven (HR+), HER2-negativen (HER2-) Mammakarzinoms haben, erfahren Sie hier im Update.

ANZEIGE

Finale OS-Analyse der MONARCH-3-Studie vorgestellt

In der MONARCH-3-Studie erhielten Patientinnen mit fortgeschrittenem HR+, HER2- Brustkrebs Abemaciclib [1,a] in Kombination mit nicht-steroidalem Aromatasehemmer (nsAI). Die finalen Daten bestätigen den in früheren Analysen beobachteten Unterschied zugunsten der Kombinationstherapie. [2] Details dazu vom SABCS 2023.

ANZEIGE

Die Bedeutung der CDK4 & 6 Inhibition beim HR+, HER2- Mammakarzinom

Es erwarten Sie praxisrelevante Patientenfälle, kompakte Studiendarstellungen, informative Experteninterviews sowie weitere spannende Inhalte rund um das HR+, HER2- Mammakarzinom.